Shattuck Labs, Inc. (STTK) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Shattuck Labs, Inc. is a clinical-stage biotechnology company developing dual-sided fusion proteins via its Agonist Redirected Checkpoint (ARC) platform. The company's lead product candidate, SL-172154, is in Phase 1B clinical trials for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company has no approved products and generates revenue solely through collaboration agreements.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $1.6 million | $0.2 million | $2.7 million | $0.3 million |
| Net Loss | $(21.6) million | $(21.3) million | $(40.1) million | $(42.1) million |
| Net Loss Per Share (Basic/Diluted) | $(0.42) | $(0.50) | $(0.79) | $(0.99) |
| Operating Expenses (Total) | $24.6 million | $22.9 million | $45.7 million | $44.7 million |
| Cash, Cash Equivalents & Investments | $105.3 million (as of June 30, 2024) | |||
| Accumulated Deficit | $346.4 million (as of June 30, 2024) | |||
| Net Cash Used in Operating Activities | N/A | $(27.1) million | $(45.1) million |
Material Changes vs. Prior Period
- Revenue Surge: Collaboration revenue increased by 704.5% in Q2 2024 compared to Q2 2023, and by 959.9% on a year-to-date basis. This growth is primarily driven by the new collaboration agreement with Ono Pharmaceutical Co., Ltd. (Ono) entered into in February 2024, alongside the completion of obligations under the ImmunoGen agreement.
- Expense Management: Research and Development (R&D) expenses increased modestly by 5.7% in Q2 2024, driven by GMP manufacturing costs for SL-172154, partially offset by decreases in preclinical research costs. General and Administrative (G&A) expenses rose 12.4% due to increased corporate costs.
- Investment Activity: The company significantly increased its investment portfolio, purchasing $63.7 million in investments during the first six months of 2024, compared to $14.8 million in the same period in 2023. Total investments grew from $5.0 million at year-end 2023 to $44.7 million at June 30, 2024.
- Cash Position: Cash and cash equivalents decreased from $125.6 million at December 31, 2023, to $60.7 million at June 30, 2024, reflecting operating cash burn and net investment purchases.
Outlook, Guidance, and Risks
- Liquidity: Management believes current cash, cash equivalents, and investments ($105.3 million) are sufficient to fund operations for at least the next 12 months (into 2026 per MD&A text). The company anticipates continued losses until product candidates are approved and commercialized.
- Clinical Progress: Recent data presented at the European Hematology Association 2024 Congress showed SL-172154 in combination with azacitidine improved clinical response and complete remission rates in HR-MDS and TP53 mutant AML patients compared to azacitidine monotherapy. The company is initiating randomized, controlled dose expansion cohorts in these populations.
- Strategic Focus: The company plans to focus later-stage clinical development on AML and HR-MDS, pausing further development in platinum-resistant ovarian cancer due to the competitive landscape.
- Risks: Key risks include the need for additional financing, the uncertainty of clinical trial outcomes, the ability to maintain orphan drug designation for SL-172154, and reliance on third-party CROs and CDMOs. The company is also subject to macroeconomic pressures including inflation and interest rates.
Investor Verification Checklist
- Verify the runway calculation based on the $105.3 million liquidity position against the current quarterly burn rate of approximately $27 million in operating cash flow.
- Confirm the status of the Ono Pharmaceutical collaboration, specifically the timeline for the Research Plan and the potential for the $217.5 million in milestone payments.
- Review the clinical trial enrollment rates for the new randomized, controlled dose expansion cohorts in AML and HR-MDS to assess the timeline for potential Phase 2/3 data readouts.
- Monitor the stock-based compensation expense, which totaled $5.1 million for the six months ended June 30, 2024, and its impact on future cash burn.
- Assess the investment portfolio composition (U.S. Treasury securities) and the impact of interest rate fluctuations on "Other Income."